Omnicell Appoints Perry A. Genova, PhD, as Chief Technology Officer
Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming pharmacy and nursing care delivery, has announced the appointment of Perry A. Genova, PhD, as Senior Vice President and Chief Technology Officer, effective March 31, 2025.
Dr. Perry A. Genova has been appointed as Omnicell’s Senior Vice President and Chief Technology Officer, effective March 31, 2025. In this role, he will spearhead the company’s technology initiatives, focusing on optimizing medication and supply management across various healthcare settings. His leadership will be crucial in advancing Omnicell’s vision of the Autonomous Pharmacy, a technology-driven approach designed to enhance efficiency, reduce errors, and improve patient outcomes through automation and AI-driven solutions.
With over 25 years of experience in product development, Officer regulatory compliance, and strategic planning, Dr. Genova has a strong track record of driving innovation in the medical device, pharmaceutical, and life sciences sectors. His previous leadership roles include positions at EndoQuest Robotics, Titan Medical USA, Centauri Robotic Surgical Systems, and GSK, where he led groundbreaking advancements in medical technology. He also holds 58 U.S. patents and played a key role in developing a class-leading insulin delivery device.
Omnicell, a leader in pharmacy automation and medication management, has been transforming healthcare since 1992 through robotics, intelligent software, and data analytics. The company’s solutions help healthcare providers improve efficiency, reduce costs, enhance supply chain control, and support regulatory compliance. With Dr. Genova’s expertise, Omnicell aims to further accelerate the development of cutting-edge solutions that Officer optimize pharmacy operations and improve patient care.
His appointment reflects Omnicell’s commitment to driving innovation in healthcare technology, ensuring its solutions continue to evolve in response to industry needs. As the company moves toward the fully Autonomous Pharmacy, Dr. Genova’s leadership will play a pivotal role in shaping the future of medication management.
With over 25 years of experience in product development, strategic planning, Officer and regulatory compliance, Dr. Genova has an impressive track record of delivering innovation, growth, and operational excellence across the medical device, pharmaceutical, and life sciences industries. His deep expertise in research and development, combined with his strategic leadership capabilities, positions him well to accelerate Omnicell’s ongoing initiatives and long-term vision.
Strategic Leadership and Innovation
Omnicell’s Executive Vice President and Chief Operating Officer, Nnamdi Njoku, expressed confidence in Dr. Genova’s ability to drive the company’s multi-year, outcome-centric growth strategy. Officer “We believe Perry’s entrepreneurial mindset will be pivotal to advancing our technology roadmap as we work to enhance clinical and operational outcomes for our customers,” said Njoku. “His ability to foster collaboration among strategic partners, internal teams, and external stakeholders will further Officer strengthen Omnicell’s commitment to transforming medication management across all care settings.”
Dr. Genova’s expertise will be central to Omnicell’s efforts to develop cutting-edge Officer solutions in pharmacy automation, artificial intelligence (AI), and data analytics, ensuring the company remains at the forefront of healthcare technology innovation. By leveraging AI-driven insights and automation, Omnicell aims to streamline medication workflows, reduce inefficiencies, and improve patient safety in hospitals, outpatient care facilities, and retail pharmacies.
About Perry Genova
Dr. Genova is widely recognized as a thought leader in medical technology and innovation. Prior to joining Omnicell, he served in executive roles at various healthcare and life sciences companies, where he led groundbreaking research and development efforts:
- Senior Vice President of Research and Development at EndoQuest Robotics, Inc. and Titan Medical USA: Spearheaded advancements in robotic-assisted surgical technologies.
- President and CEO at Centauri Robotic Surgical Systems, Inc. and Oncoscope, Inc.: Led innovative efforts in robotic surgery and cancer diagnostics.
- Vice President at GSK plc (formerly GlaxoSmithKline plc) and Kos Pharmaceuticals, Inc.: Played a key role in developing novel pharmaceutical and medical technologies.
Among his notable achievements, Dr. Genova built an $800 million division at Kos Pharmaceuticals, Inc. and contributed to the development of a class-leading reservoir insulin device. He holds 58 issued U.S. patents covering a diverse range of medical and consumer technologies. His academic background includes BS, MS, and PhD degrees in engineering from the University of North Carolina, further underscoring his technical expertise and commitment to innovation.
Omnicell’s Commitment to the Autonomous Pharmacy
Since its founding in 1992, Omnicell has been dedicated to revolutionizing pharmacy and nursing care through technology-driven solutions. The company’s comprehensive portfolio includes robotics and smart devices, intelligent software workflows, and advanced data analytics, all designed to improve medication management, enhance supply chain control, and support compliance in healthcare facilities worldwide.
Omnicell’s solutions are built on the principles of automation, intelligence, and expert services, helping healthcare organizations achieve:
- Cost Savings: Optimizing inventory management to reduce medication waste and lower operational expenses.
- Labor Efficiency: Automating manual processes to allow healthcare professionals to focus on patient care.
- Revenue Growth: Establishing new revenue streams through enhanced medication adherence and pharmacy services.
- Regulatory Compliance: Supporting adherence to industry regulations and best practices for medication safety.
By integrating AI, machine learning, and cloud-based analytics, Omnicell is actively working toward realizing the Autonomous Pharmacy, a framework designed to minimize human error, improve patient outcomes, and streamline healthcare operations.
Looking Ahead
With Dr. Genova at the helm of Omnicell’s technology strategy, the company is poised to accelerate innovation in medication management. His appointment marks a significant step forward in Omnicell’s mission to enhance healthcare efficiency, safety, and accessibility through cutting-edge digital solutions. As the healthcare industry continues to evolve, Omnicell remains committed to delivering transformative technologies that support better patient care and operational excellence.
